• Vapogenix

  Led · Grant · Nov 2020

  Vapogenix is a clinical-stage Houston-based company developing topical formulations of volatile anesthetics (VAs) as non-opioid, lidocaine-free analgesics. Its lead program is VPX638 (sevoflurane), part of a platform of patented VA formulations for localized treatment of painful conditions. The company reported successful Phase I SBIR studies with Texas Heart Institute showing analgesic and anti-inflammatory properties, and a Phase 2 clinical trial last year demonstrated rapid onset, sustained pain relief, and reduced opioid use for wounds. Vapogenix holds a global intellectual property portfolio with 43 issued or allowed patents. The Phase II SBIR award will fund formulation development and characterization of anti-inflammatory and analgesic profiles in animal disease models to support an IND. Vapogenix is seeking additional funding and partners to advance clinical development and commercialization. Vapogenix develops a locally-acting, topical non-opioid analgesic based on volatile anesthetics, formulated into gels and liquids. The company intends to treat painful conditions including wounds, combat-related injuries, osteoarthritis, and muscular and inflammatory conditions. Vapogenix raised $8.2M in funding to advance its program. The proceeds are planned to begin a Phase 2 Proof-of-Concept study for Project AWARD (A Wound Analgesic with RapiD action) in 2017. Investors in the round included Pamoja Capital, prominent pain physicians and others. The company is led by CEO and Co-Founder Danguole Altman and Co-Founder and Scientific Advisory Board Chairman Allen Burton, MD. Vapogenix is developing a rapidly acting topical analgesic designed to penetrate skin within minutes. The company reformulates liquid anesthetics—typically vaporized inhalants used during surgery—into topical patches or liquids. Its lead program has progressed to Phase II trials, while products for wound and inflammatory pain remain at earlier stages. Vapogenix filed an IND with the FDA this week to advance clinical testing. Financially, regulatory filings disclose $2.1M in a recent financing; the company says it has raised $3M from high-net-worth individuals in a Series B set to close July 31, and holds a $2M grant from the Texas Emerging Technology Fund. Management says these funds are helping the company "come out of the Valley of Death."

• Modulim

  Participated · Grant · Nov 2017

  Modulated Imaging develops medical-photonics and informatics solutions powered by its Spatial Frequency Domain Imaging (SFDI) platform to assess tissue health. Its core product, the FDA-cleared Clarifi Imaging System, provides quantitative assessment of circulatory compromise to help identify patients at risk for diabetic foot ulcers and other vascular complications. The SFDI technology measures microvascular tissue oxygenation and hemoglobin concentration and distribution to detect compromised perfusion early. The company positions Clarifi to enable earlier clinical intervention with the potential to save limbs and lives and reduce treatment costs. Recent financing is being used to advance commercialization of Clarifi and broaden clinical adoption. Modulated Imaging develops light-based, non-invasive imaging systems (Ox-Imager CS) that provide both surface and subsurface views plus a digital color photograph to assess tissue health and identify lower-limb vascular issues. The company received FDA clearance earlier this year for the Ox-Imager CS. Proceeds from its recent financing will support key clinical studies — expanding trials beyond California and Arizona — and accelerate development of a miniaturized next-generation Ox-Imager device. Modulated Imaging closed a $2.86 million Series A and also received a $1.2 million Commercialization Readiness grant from NIAMS (NIH). This financing is the company's second round since July of last year. The company was founded in 2008 and is based in Irvine, Calif. Modulated Imaging is an Irvine, CA–based developer of imaging systems for scientific and medical applications. The company develops patented Spatial Frequency Domain Imaging (SFDI) tissue-imaging devices intended to help medical, research and aesthetics professionals prevent, diagnose and treat underlying skin conditions. Its first medical device, the Ox-Imager CS, is pending FDA clearance and is targeted to rapid, wide-area perfusion studies across applications from vascular labs to chronic wound management. Modulated Imaging also sells the Reflect RS scientific instrument. The company has been self-funded through sales of the Reflect RS and approximately $8M in research grants from the National Institutes of Health and the Department of Defense. It intends to use the newly raised funds to continue development of its medical technology.

No current team members are available.